Calvin

2018.11.03

I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy A Potential Global First-in-Class Long-Acting IL-7

2018.10.14

First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)

2018.09.27

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody? Platform for Three Bispecific Antibody Programs

2018.09.20

I-Mab Wins Frost& Sullivan “2018 Best R&D Innovator Award (Biopharma Category)”

2018.08.10

I-Mab’s Announces China Clinical Trial Approval of Long-acting hGLP-1 To Treat Type 2 Diabetes

2018.08.08

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

2018.08.01

I-Mab Biopharma Announces New CFO

2018.07.26

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies